VAXIMM AG is a private, clinical stage, Swiss/German biotech developing oral T-cell immunotherapies against cancer. VAXIMM’s technology is based on first in-class oral T-cell activators that can be readily adapted to target a wide range of cancer-related antigens. Lead product candidate, VXM01, is designed to activate T-cells to attack the tumor vasculature, and, in several tumor types, attack cancer cells directly.
VXM01 has orphan designation for the EU and the US for glioma. VAXIMM’s neoantigen program (VXM NEO) is in preclinical development and has shown immune proof of concept; the Company’s platform allows for fast generation and delivery of personalized T-cell vaccines and may overcome key issues with other neoantigen approaches. Additional programs are in preclinical development.
VAXXIMM AG at a glance:
|Field of Activity||
|Ownership Structure and Financing||
|Technology||VAXIMM’s technology is based on first-in-class oral T-cell activators that can be readily adapted to target a wide range of
cancer-related antigens. The platform is based on the live attenuated bacterial vaccine strain Ty21, which has been administered to millions of people as a prophylactic vaccine to temporarily protect them from typhoid fever. This strain has been proven to be safe and well tolerated. All immunotherapies resulting from this
platform are taken orally by the patient. The platform is suitable for addressing multiple targets with one treatment and can be combined with additional immunotherapies.
|Date of Incorporation / Number of Employees||2008 / 10|
|Social media||LinkedIn: VAXIMM AG